Elena Guerini
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL.
Journal: Clinical pharmacology and therapeutics
Published: January 15, 2025
Middle-Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 25, 2024
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
Journal: CPT: pharmacometrics & systems pharmacology
Published: September 23, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Journal: Cancer chemotherapy and pharmacology
Published: August 04, 2022
Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Journal: ESMO open
Published: February 10, 2022
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Journal: European journal of drug metabolism and pharmacokinetics
Published: August 17, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Journal: Investigational new drugs
Published: April 15, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 08, 2021
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Journal: Clinical pharmacology and therapeutics
Published: February 02, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Journal: Investigational new drugs
Published: October 30, 2020
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Journal: The AAPS journal
Published: February 05, 2020
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Journal: Journal of clinical pharmacology
Published: April 26, 2018
Last Updated: 09/26/2026